

THE CHANGING FACE OF UK DRUG DISCOVERY

by the numbers



Increased globalisation and a shift towards more open innovation has led to changes in the environment that fosters medical breakthroughs. The report produced by TBR for the Association for the British Pharmaceutical Industry (ABPI) found out how the last 10 years have impacted the UK environment.




60% OF LARGE COMPANIES HAVE INCREASED INVESTMENT

in outsourced and collaborative drug discovery work in the UK in the last 10 years.



3/4 OF MID & LARGE COMPANIES WORK IN PARTNERSHIP

on drug discovery with academia, charities, or biotech companies in the UK according to those sampled.



70% OF CROs HAVE INCREASED THEIR DRUG DISCOVERY WORK

or begun trading in the last 10 years.



AS MANY CROs HAVE CLIENTS FROM THE US AND EUROPE

for drug discovery work as from the UK.



OVERALL THE UK IS LOSING OUT ON DRUG DISCOVERY INVESTMENT

by large companies compared to global investment.